Edgewise Therapeutics (NASDAQ:EWTX) Upgraded at HC Wainwright

HC Wainwright upgraded shares of Edgewise Therapeutics (NASDAQ:EWTX) to a strong-buy rating in a research note published on Thursday morning,Zacks.com reports. HC Wainwright also issued estimates for Edgewise Therapeutics’ Q1 2026 earnings at ($0.43) EPS, Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.51) EPS and Q4 2026 earnings at ($0.60) EPS.

A number of other analysts have also recently weighed in on the stock. Stifel Nicolaus set a $25.00 price target on shares of Edgewise Therapeutics in a research report on Thursday. Wedbush decreased their target price on Edgewise Therapeutics from $35.00 to $32.00 and set an “outperform” rating for the company in a research report on Friday, November 7th. Wall Street Zen lowered Edgewise Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Royal Bank Of Canada boosted their price target on Edgewise Therapeutics from $49.00 to $50.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Finally, Evercore restated an “outperform” rating and issued a $45.00 price target on shares of Edgewise Therapeutics in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Edgewise Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.36.

Edgewise Therapeutics Stock Performance

NASDAQ EWTX opened at $30.44 on Thursday. Edgewise Therapeutics has a one year low of $10.60 and a one year high of $31.82. The company’s 50 day moving average price is $27.62 and its 200 day moving average price is $21.22. The firm has a market capitalization of $3.22 billion, a price-to-earnings ratio of -18.67 and a beta of 0.27.

Edgewise Therapeutics (NASDAQ:EWTX) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.04). Sell-side analysts forecast that Edgewise Therapeutics will post -1.45 EPS for the current fiscal year.

Insider Activity

In related news, Director Badreddin Edris sold 115,471 shares of the company’s stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $29.44, for a total value of $3,399,466.24. Following the sale, the director directly owned 19,820 shares of the company’s stock, valued at $583,500.80. This represents a 85.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 23.20% of the company’s stock.

Institutional Investors Weigh In On Edgewise Therapeutics

A number of institutional investors have recently modified their holdings of EWTX. Bessemer Group Inc. grew its stake in Edgewise Therapeutics by 1,170.3% in the third quarter. Bessemer Group Inc. now owns 2,350 shares of the company’s stock worth $38,000 after purchasing an additional 2,165 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in Edgewise Therapeutics during the 2nd quarter worth approximately $45,000. Jones Financial Companies Lllp acquired a new position in shares of Edgewise Therapeutics in the 1st quarter worth approximately $47,000. Seven Fleet Capital Management LP bought a new stake in shares of Edgewise Therapeutics in the 4th quarter valued at approximately $50,000. Finally, Steward Partners Investment Advisory LLC raised its position in shares of Edgewise Therapeutics by 23.9% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,854 shares of the company’s stock valued at $71,000 after acquiring an additional 550 shares in the last quarter.

Trending Headlines about Edgewise Therapeutics

Here are the key news stories impacting Edgewise Therapeutics this week:

• Positive Sentiment: Multiple near‑term clinical catalysts could drive upside: management flagged CIRRUS‑HCM 12‑week data for EDG‑7500 and Phase 1 healthy‑adult data for EDG‑15400 (with planned heart‑failure studies) expected in H1 2026, and pivotal GRAND CANYON results for sevasemten in Becker muscular dystrophy anticipated in Q4 2026. These readouts materially de‑risk the pipeline and are likely the main reason investors are buying the stock. PR Newswire: Q4 & Full Year 2025 Results
• Positive Sentiment: Company increased R&D investment in Q4, signaling management is funding those near‑term trials and pivotal work — a positive for long‑term value creation if the upcoming readouts are favorable. BizWest: R&D boost
• Neutral Sentiment: Analyst modeling: HC Wainwright published quarterly EPS forecasts for 2026 (Q1 -$0.43, Q2 -$0.47, Q3 -$0.51, Q4 -$0.60; full‑year -$1.45). These estimates reinforce expectations of continued operating losses as the company advances trials; they provide a near‑term earnings framework but don’t change the pipeline narrative. MarketBeat: HC Wainwright estimates
• Neutral Sentiment: Valuation discussion: recent coverage (e.g., Yahoo Finance) examines EWTX’s strong multi‑year returns and recent momentum, useful for investors assessing whether current share price already reflects upcoming catalysts. Yahoo Finance: Valuation piece
• Negative Sentiment: Q4 earnings miss and near‑term financial drag: Edgewise reported EPS of ($0.47) for the quarter, missing the consensus ($0.43). The combination of the miss and higher R&D spend increases short‑term risk and means more funding will likely be required before positive cash flow. Press Release: Q4 Results

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.